Is FTEXX or ABBV a better dividend investment in 2026?

FTEXX currently yields 200.00% with a 5% 5-year dividend growth rate. ABBV yields 3.09% with 8.9% growth. The better choice depends on your goal: FTEXX offers higher current income.

What is the dividend yield difference between FTEXX and ABBV?

FTEXX has a forward dividend yield of 200.00% ($2.00/share annually). ABBV yields 3.09% ($6.65/share annually). The yield gap is 196.91 percentage points.

Home › Compare › FTEXX vs ABBV

FTEXX vs ABBV: Dividend Comparison 2026

FTEXX yields 200.00% · ABBV yields 3.09%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 FTEXX wins by $119.26M in total portfolio value

INVESTMENT

TIME HORIZON10 years

FTEXX

● Live price

200.00%

Share price

$1.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$119.36M

Annual income

$60,176,096.29

Full FTEXX calculator →

ABBV

AbbVie Inc.

● Live price

3.09%

Share price

$214.96

Annual div

$6.65

5Y div CAGR

40.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$103.7K

Annual income

$25,324.79

Full ABBV calculator →

Portfolio growth — FTEXX vs ABBV

📍 FTEXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	FTEXX	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, FTEXX + ABBV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

FTEXX pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FTEXX

Annual income on $10K today (after 15% tax)

$17,000.00/yr

After 10yr DRIP, annual income (after tax)

$51,149,681.85/yr

ABBV

Annual income on $10K today (after 15% tax)

$262.96/yr

After 10yr DRIP, annual income (after tax)

$21,526.07/yr

At 15% tax rate, FTEXX beats the other by $51,128,155.77/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FTEXX + ABBV for your $10,000?

FTEXX: 50%ABBV: 50%

100% ABBV50/50100% FTEXX

Portfolio after 10yr

$59.73M

Annual income

$30,100,710.53/yr

Blended yield

50.39%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FTEXX

No analyst data

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+19.2% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FTEXX buys

ABBV buys

No recent congressional trades found for FTEXX or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricFTEXXABBV

Forward yield	200.00% ✓	3.09%
Annual dividend / share	$2.00	$6.65 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.6% ✓
Portfolio after 10y	$119.36M ✓	$103.7K
Annual income after 10y	$60,176,096.29 ✓	$25,324.79
Total dividends collected	$112.49M ✓	$62.2K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: FTEXX vs ABBV ($10,000, DRIP)

Year	FTEXX Portfolio	FTEXX Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$30,700	$20,000.00	$11,555	$434.96	+$19.1K → FTEXX
2	$90,232	$57,383.18	$13,485	$635.47	+$76.7K → FTEXX
3	$254,173	$157,624.56	$15,933	$937.67	+$238.2K → FTEXX
4	$686,927	$414,961.74	$19,118	$1,400.80	+$667.8K → FTEXX
5	$1,783,118	$1,048,106.39	$23,384	$2,125.24	+$1.76M → FTEXX
6	$4,450,613	$2,542,677.12	$29,290	$3,286.81	+$4.42M → FTEXX
7	$10,693,420	$5,931,263.38	$37,776	$5,205.38	+$10.66M → FTEXX
8	$24,760,608	$13,318,648.86	$50,495	$8,488.44	+$24.71M → FTEXX
9	$55,315,649	$28,821,798.66	$70,497	$14,346.44	+$55.25M → FTEXX
10	$119,363,841	$60,176,096.29	$103,718	$25,324.79	+$119.26M → FTEXX

FTEXX vs ABBV: Complete Analysis 2026

FTEXX — Stock

FTEXX is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in FTEXX shares.

Full FTEXX Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

📬

Get this FTEXX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FTEXX vs SCHD FTEXX vs JEPI FTEXX vs O FTEXX vs KO FTEXX vs MAIN FTEXX vs JNJ FTEXX vs MRK FTEXX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.